Novo Nordisk A/S: The Acquisition of Catalent by Novo Holdings, and the Related Acquisition by Novo Nordisk of Three Manufacturing Sites From Novo Holdings, Is Cleared to Close
Novo Nordisk A/S: The Acquisition of Catalent by Novo Holdings, and the Related Acquisition by Novo Nordisk of Three Manufacturing Sites From Novo Holdings, Is Cleared to Close
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.
丹麦巴格斯瓦德，2024年12月14日——截至今天，与Novo Holdings A/S待购的Catalent, Inc.（Catalent）收购审查相关的所有监管条件，包括美国的时间协议到期，均已满足。Catalent是一家全球合同开发和制造组织，总部位于美国新泽西州。各方现在可以自由完成交易，以及Novo Nordisk随后从Novo Holdings A/S收购三家Catalent制造基地的交易。
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
收购这三家制造基地的协议于2024年2月5日宣布。有关更多信息，请查看公司的公告。
Novo Nordisk now expects the acquisition to be completed in the coming days.
Novo Nordisk现在预计收购将在接下来的几天内完成。
Upon completion, the acquisition is expected to impact the financial outlook as issued on 6 November 2024, with a low single-digit negative impact on operating profit growth and to negatively impact free cash flow with the 11.7 billion USD acquisition price. The ongoing share buyback programme of 20 billion DKK is not impacted.
完成后，预计该收购将对2024年11月6日发布的财务前景产生影响，营业利润增长将受到低个位数的负面影响，并将对自由现金流产生负面影响，收购价格为117亿 美元指数。进行中的200亿丹麦克朗的股票回购计划不受影响。
For 2025, the acquisition is expected to have a mid single-digit negative impact on operating profit growth. The acquisition will be mainly debt-financed, with interest payments negatively impacting net financial items. Novo Nordisk's capital allocation priorities focus on internal growth investments, including supply chain expansions, dividends as well as external growth opportunities, including acquiring the three manufacturing sites. Consequently, Novo Nordisk is not expecting to initiate a share buyback programme in 2025.
到2025年，这项收购预计将对营业利润增长产生中等个位数的负面影响。这项收购主要将通过债务融资，利息支付将对净财务项目产生负面影响。诺和诺德的资本分配优先考虑内部增长投资，包括供应链扩展、分红派息以及外部增长机会，包括收购这三家制造业-半导体。因而，诺和诺德预计在2025年不会启动股票回购计划。
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
诺和诺德是一家领先的全球医疗保健公司，成立于1923年，总部位于丹麦。我们的目标是推动变革，以击败严重的慢性疾病，这基于我们在糖尿病领域的传统。我们通过开创科学突破、扩大药品的可及性，以及努力预防和最终治愈疾病来实现这一目标。诺和诺德在80个国家雇佣约72,000名员工，并在约170个国家销售我们的产品。诺和诺德的B类股票在纳斯达克哥本哈根上市（Novo-B）。其美国存托股票（ADRs）在纽约证券交易所上市（NVO）。有关更多信息，请访问novonordisk.com、Facebook、Instagram、X、LinkedIn和YouTube。
Contacts for further information
更多信息的联系人
| Media: | |
|
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
|
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
|
Sina Meyer +45 3079 6656 azey@novonordisk.com |
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
|
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
| 媒体： | |
| 安布雷·詹姆斯-布朗 +45 3079 9289 abmo@novonordisk.com |
莉兹·斯克尔博娃（美国） +1 609 917 0632 lzsk@novonordisk.com |
| 投资者： | |
| 雅各布·马丁·维博格·罗德 +45 3075 5956 jrde@novonordisk.com |
大卫·海伯格·兰斯特德 +45 3077 6915 dhel@novonordisk.com |
| 西娜·梅耶 +45 3079 6656 azey@novonordisk.com |
伊达·沙普·梅尔沃德 +45 3077 5649 idmg@novonordisk.com |
| 弗雷德里克·泰勒·皮特 +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 96 / 2024
公司公告第 96 / 2024 号
Attachment
附件
- PR241214-Catalent-clearance-to-close
- PR241214-Catalent-关闭清算
